慢性阻塞性肺疾病和肺心病患者血浆TXB_2、6-Keto-PGF_(1a)的测定

Measurements of Plasma TXB_2,6-Keto-PGF_(1a) in Chronic Obstructive Pulmonary Disease(COPD)and Pulmonary Heart Diseases.

目的 :探讨慢性阻塞性肺疾病 (COPD)和肺心病患者血浆血栓素 (TXB2 )和 6 -酮 -前列环素F1a(6 -Keto -PGF1a)的变化及临床意义。方法 :采用放射免疫法测定血浆TXB2 、6 -Keto -PGF1a的浓度。结果 :COPD患者血浆TXB2 与对照组比较无明显差异 (P >0 0 5 )。肺心病急性发作期TXB2 明显高于对照组及COPD组 ,差异有显著性 (P <0 0 1)。COPD组及肺心病组 6 -Keto -PGF1a与对照组比较差异有显著性 (P <0 0 1)。结论 :TXB2 在肺心病肺动脉高压的发生发展中起着重要的作用。

Objective: To investigate the changes of TXB 2 and 6-Keto-PGF 1a in patients of COPD and pulmonary heart disease.Methods:The radioimmunoassay (RIA) were used to measure levels of plasma TXB 2 and 6-Keto-PGF 1a.Results:Level of plasma TXB 2 in COPD was similar to that of control's (P>0 05).The plasma TXB 2 in pulmonary heart disease patients were higer than those of control's and COPD(P<0 01).the plasma 6-Keto-PGF 1a in COPD and pulmonary heart disease groups were higher than that of control's (P<0 01).Conclusion:The results of this study suggest that TXB 2 have an important effect in the development of high pulmonary arterial Pressure in pulmonary heart disease.